---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-099389"
form_type: "8-K"
ticker: "RGEN"
cik: "0000730272"
company_name: "REPLIGEN CORP"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:52:52.486583+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance

## Summary
- Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
- GAAP EPS $0.26 vs $0.10; adjusted EPS $0.37 vs $0.40.
- Orders grew >20% YoY and sequentially, 8th consecutive quarter of orders exceeding non-COVID revenue.
- Raises FY2025 revenue guidance to $715-$735M, organic non-COVID growth 12.5%-15.5%.
- All franchises grew YoY; consumables >20%, biopharma +20%, all geographies mid-teens.

## SEC filing metadata
- accession: 0000950170-25-099389
- form_type: 8-K
- ticker: RGEN
- cik: 0000730272
- company_name: REPLIGEN CORP
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/0000950170-25-099389-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/730272/000095017025099389/rgen-20250729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-099389
- JSON: https://secwatch.observer/filing/0000950170-25-099389.json
- Plain text: https://secwatch.observer/filing/0000950170-25-099389.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.